DOCSLIB.ORG

First Unaffected Pregnancy Using Preimplantation Genetic Diagnosis for Sickle Cell Anemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
First Unaffected Pregnancy Using Preimplantation Genetic Diagnosis for Sickle Cell Anemia ORIGINAL CONTRIBUTION First Unaffected Pregnancy Using Preimplantation Genetic Diagnosis for Sickle Cell Anemia Kangpu Xu, PhD Context Sickle cell anemia is a common autosomal recessive disorder. However, pre- Zhong Ming Shi, MD implantation genetic diagnosis (PGD) for this severe genetic disorder previously has not been successful. Lucinda L. Veeck, MLT, DSc Objective To achieve pregnancy with an unaffected embryo using in vitro fertiliza- Mark R. Hughes, MD, PhD tion (IVF) and PGD. Zev Rosenwaks, MD Design Laboratory analysis of DNA from single cells obtained by biopsy from em- ICKLE CELL ANEMIA IS ONE OF THE bryos in 2 IVF attempts, 1 in 1996 and 1 in 1997, to determine the genetic status of each embryo before intrauterine transfer. most common human autoso- mal recessive disorders. It is Setting University hospital in a large metropolitan area. caused by a mutation substitut- Patients A couple, both carriers of the recessive mutation for sickle cell disease. Sing thymine for adenine in the sixth Interventions Standard IVF treatment, intracytoplasmic sperm injection, embryo bi- codon (GAG to GTG) of the gene for the opsy, single-cell polymerase chain reaction and DNA analyses, embryo transfer to uterus, b-globin chain on chromosome 11p, pregnancy confirmation, and prenatal diagnosis by amniocentesis at 16.5 weeks’ ges- thereby encoding valine instead of glu- tation. tamic acid in the sixth position of the Main Outcome Measure DNA analysis of single blastomeres indicating whether globin chain. The frequency of sickle cell embryos carried the sickle cell mutation, allowing only unaffected or carrier embryos trait (carrier status) among the African to be transferred. American population at birth is about Results The first IVF attempt failed to produce a pregnancy. Of the 7 embryos ana- 8%, and the incidence of sickle cell ane- lyzed in the second attempt, PGD indicated that 4 were normal and 2 were carriers; mia at birth is 0.16%, or 1 per 625 diagnosis was not possible in 1. Three embryos were transferred to the uterus on the births.1 Furthermore, the widespread fourth day after oocyte retrieval. A twin pregnancy was confirmed by ultrasonogra- presence of the sickle gene in other eth- phy, and subsequent amniocentesis revealed that both fetuses were unaffected and nic groups has also been confirmed.2 For were not carriers of the sickle cell mutation. The patient delivered healthy twins at 39 example, in urban centers in the United weeks’ gestation. States, nearly 10% of patients with vari- Conclusion This first unaffected pregnancy resulting from PGD for sickle cell ane- ous sickling disorders identify them- mia demonstrates that the technique can be a powerful diagnostic tool for carrier couples selves as non–African American.3 who desire a healthy child but wish to avoid the difficult decision of whether to abort Children affected with sickle cell ane- an affected fetus. mia experience recurrent episodes of pain JAMA. 1999;281:1701-1706 www.jama.com (during sickle cell crises) and increased rican American children aged 1 to 4 years Author Affiliations: The Center for Reproductive susceptibility to potentially life- due to sickle cell disease.4 Life expec- Medicine and Infertility and the Department of Ob- threatening conditions, including bac- stetrics and Gynecology, Weill Medical College of Cor- tancy for persons with sickle cell dis- terial infections, cerebrovascular acci- nell University, New York, NY (Drs Xu, Shi, Veeck, and ease varies and there is an age-related Rosenwaks); and the Department of Reproductive Ge- dents, and organ failure. According to US pattern in mortality rates: a peak in pa- netics, Wayne State University, Detroit Medical Cen- statistics collected between 1981 and ter, Detroit, Mich (Dr Hughes). tients younger than 5 years, with a 1992, there were 6.8 deaths per 1000 Af- Corresponding Author and Reprints: Zev Rosen- gradual increase starting in late adoles- waks, MD, The Center for Reproductive Medicine and 5 Infertility, Weill Medical College of Cornell Univer- cence. Progress in the treatment of sickle sity, 505 E 70th St, Room HT326a, New York, NY See also Patient Page. 6 cell disease has been slow. At present, 10021 (e-mail: [email protected]). ©1999 American Medical Association. All rights reserved. JAMA, May 12, 1999—Vol 281, No. 18 1701 Downloaded From: https://jamanetwork.com/ on 09/23/2021 PREIMPLANTATION DIAGNOSIS FOR SICKLE CELL ANEMIA there is no satisfactory treatment for the because she was carrying fetuses af- digested with the restriction enzyme sickling condition, although blood trans- fected with sickle cell anemia. Genetic DdeI (GIBCO/BRL, Rockville, Md) for fusion may reduce the risk of a first stroke diagnosis indicated that both female and 3 hours. Subsequently, 10 µL of di- in children7 and gene therapy holds male partners were carriers of the sickle gested product was run on a 10% acryl- promise for a curative approach.8 cell mutation. After extensive counsel- amide gel. On completion of electro- Early prenatal diagnosis of the dis- ing, the couple gave informed consent phoresis, the gel was stained with ease is critical because it allows a couple and elected to undergo preimplanta- ethidium bromide and photographed by to consider pregnancy termination as tion genetic diagnosis. The study was UV transillumination. As predicted, un- an option. The first DNA diagnostic approved by the Weill Medical Col- affected DNA showed 3 bands (201, 90, procedure for prenatal purposes was re- lege of Cornell University (New York, and 74 base pairs [bp]), carrier DNA ported 20 years ago.9 Subsequently, it NY) Institutional Review Board. showed 4 bands (291, 201, 90, and 74 was recognized that the mutation it- To confirm the genetic status of the bp), and an affected homozygous self affected the cleavage site of a re- couple and establish a protocol for sample showed only 2 bands (291 and striction enzyme, DdeI, that could rec- single-copy gene amplification from 74 bp). Testing of single lymphocytes ognize the DNA sequence of CTNAG single cells, blood was collected from from the male and female subjects (N = A, T, C, or G). While DNA from a both partners. Lymphocytes were iso- showed the same predicted patterns (4 normal allele (CTGAG) would be di- lated using Ficoll-Paque density gradi- bands of predicted sizes), together with gested by the enzyme, DNA from an af- ent separation (Pharmacia Biotech Inc, an unaffected DNA control (3 bands) fected allele in which A is substituted Piscataway, NJ) with the protocol pro- (FIGURE 1). by T (CTGTG) would not.10,11 The re- vided by the manufacturer. Single lym- The IVF procedure has been de- sulting differences between DNA frag- phocytes were loaded into 0.5-mL tubes scribed previously.20 Briefly, to ensure ment sizes can then be recognized by containing 5 µL of lysis buffer19 and that several embryos would become electrophoresis, thus forming the ba- stored at −20°C before trial testing. available for DNA analysis, multiple sis for diagnosis. With the advent of On the day of preliminary trial test- ovarian follicular development was ini- polymerase chain reaction (PCR), rapid ing, sample tubes were removed from the tiated with gonadotropin therapy. Af- DNA analysis methods have become freezer and heated to 65°C for 10 min- ter pituitary desensitization with go- available, and these techniques are now utes before they were placed back on ice. nadotropin hormone–releasing widely used for prenatal diagnosis.12-16 Five microliters of neutralization buffer hormone agonist (leuprolide acetate, An alternative and powerful diagnos- was added to each tube. A nested PCR TAP Pharmaceutical, Chicago, Ill), tic tool for identifying sickle cell status approach was used for the amplifica- ovarian stimulation was begun on day in embryos is preimplantation genetic di- tion of the region surrounding the sickle 3 of the ensuing menstrual cycle using agnosis (PGD), which became possible cell mutation. The primers used have intramuscular administration of a com- nearly a decade ago.17 Preimplantation been described previously.17,19 Polymer- bination of urofollitropin (75 U of genetic diagnosis takes advantage of as- ase chain reaction was performed after pure follicle-stimulating hormone) sisted reproductive techniques in con- adding a standard mixture of all com- and menotropins (150 U of follicle- junction with modern molecular meth- ponents, including 2.5 mmol of Mg2+, 0.2 stimulating hormone and luteinizing ods. With PGD, the genetic status of an mmol of dNTPs (containing dATP, hormone) (Serono Laboratories, Nor- embryo can be determined before trans- dCTP, dGTP, and dTTP, Perkin Elmer, well, Mass). Follicular growth was fer into the uterus after in vitro fertiliza- Foster City, Calif), 100 ng of primers, monitored by daily serum estradiol lev- tion (IVF), thus eliminating the risks of and2UofTaqpolymerase (AmpliTaq, els and pelvic ultrasonograms. To in- bearing a child with the disease. Perkin-Elmer). A hot start at 95°C was duce final oocyte maturation, 3300 IU While PGD for sickle cell anemia has applied for 3 minutes to ensure com- of human chorionic gonadotropin was been performed in the mouse model,18 plete denaturation of the template. For administered when 2 follicles of 18 mm routine clinical application in the hu- the PCR profile, the following param- in average diameter were observed on man previously has not been success- eters were used: 93°C denaturation for ultrasonogram. Transvaginal oocyte re- ful. In this article, we describe our ex- 30 seconds; 50°C for 40 seconds for an- trieval was performed 35 hours later. perience using PGD to determine the nealing; and 72°C for 45 seconds for ex- To avoid sperm contamination and pos- precise genetic status of embryos gen- tension. A total of 20 amplification cycles sible amplification of sperm DNA, in- erated by assisted reproduction for a were applied for outer primers.
Load more

Recommended publications
  • In Vitro Fertilization for Polycystic Ovarian Syndrome
    CLINICAL OBSTETRICS AND GYNECOLOGY Volume 64, Number 1, 39–47 Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. In Vitro Fertilization for Polycystic Ovarian Syndrome JESSICA R. ZOLTON, DO,* and SAIOA TORREALDAY, MD† *Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; and †Walter Reed National Military Medical Center, Bethesda, Maryland Abstract: In vitro fertilization is indicated for infertile treatment for infertility. Guidelines indi- women with polycystic ovarian syndrome (PCOS) after cate that IVF should be offered after failed unsuccessful treatment with ovulation induction agents or in women deemed high-risk of multiple gestations ovulation induction with oral agents or 1 who are ideal candidates for single embryo transfers. gonadotropin treatment. However, due to PCOS patients are at increased risk of ovarian hyper- the risk of twins and higher order multi- stimulation syndrome; therefore, attention should be ples, which is more commonly seen when made in the choice of in vitro fertilization treatment gonadotropin medications are utilized, protocol, dose of gonadotropin utilized, and regimen to achieve final oocyte maturation. Adopting these strat- IVF may be considered after failed ovula- egies in addition to close monitoring may significantly tion induction with clomiphene citrate or reduce the ovarian hyperstimulation syndrome risk. letrozole.2 In addition, PCOS patients are Future developments may improve pregnancy out- ideal candidates for consideration of elec- comes and decrease complications in PCOS women tive single embryo transfer to mitigate the undergoing fertility treatment. Key words: infertility, in vitro fertilization, polycystic risk of multiple pregnancies while under- ovarian syndrome, ovarian hyperstimulation syn- going IVF.
    [Show full text]
  • Quadrupling Efficiency in Production of Genetically Modified Pigs Through
    Quadrupling efficiency in production of genetically PNAS PLUS modified pigs through improved oocyte maturation Ye Yuana,b,1,2,3, Lee D. Spatea,1, Bethany K. Redela, Yuchen Tiana,b, Jie Zhouc, Randall S. Prathera, and R. Michael Robertsa,b,2 aDivision of Animal Sciences, University of Missouri, Columbia, MO 65211; bBond Life Sciences Center, University of Missouri, Columbia, MO 65211; and cDepartment of Obstetrics, Gynecology and Women’s Health, University of Missouri School of Medicine, Columbia, MO 65212 Contributed by R. Michael Roberts, May 23, 2017 (sent for review March 15, 2017; reviewed by Marco Conti and Pablo Juan Ross) Assisted reproductive technologies in all mammals are critically Once cumulus–oocyte complexes (COCs) are removed from the dependent on the quality of the oocytes used to produce embryos. follicular environment and placed into culture, a proportion of the For reasons not fully clear, oocytes matured in vitro tend to be much oocytes usually resume meiosis spontaneously. This promiscuous less competent to become fertilized, advance to the blastocyst stage, progression to metaphase II most probably occurs as the result of a and give rise to live young than their in vivo-produced counterparts, reduced influx of cGMP from the surrounding cumulus cells into particularly if they are derived from immature females. Here we show the oocyte. cGMP maintains high intracellular cAMP concentra- that a chemically defined maturation medium supplemented with tions by inhibiting the phosphodiesterase responsible for cAMP three cytokines (FGF2, LIF, and IGF1) in combination, so-called “FLI hydrolysis (15–17). An inappropriate drop in the concentrations of medium,” improves nuclear maturation of oocytes in cumulus–oocyte the cyclic nucleotides that control meiotic resumption causes un- complexes derived from immature pig ovaries and provides a twofold synchronized nuclear and cytoplasmic maturation of the oocytes, increase in the efficiency of blastocyst production after in vitro fertil- thereby compromising their proper development (18).
    [Show full text]
  • In Vitro Maturation of Oocytes Derived from the Brown Bear (Ursus Arctos)
    Journal of Reproduction and Development, Vol. 53, No. 3, 2007 —Research Note— In Vitro Maturation of Oocytes Derived from the Brown Bear (Ursus Arctos) Xi-Jun YIN1), Hyo-Sang LEE1), Eu-Gene CHOI1), Xian-Feng YU1), Gye-Young PARK1), Inhyu BAE1), Chul-Ju YANG1), Dong-Hwan OH1), Nam-Hung KIM2) and Il-Keun KONG1) 1)Department of Animal Science and Technology, Sunchon National University, Suncheon, JeonNam 540-742 and 2)Department of Animal Sciences, Chungbuk National University, Cheongju, Chungbuk 361-763, Korea Abstract. This study was conducted to determine whether meiotic maturation could be induced in ovarian oocytes from the American brown bear (Ursus arctos), a model for gamete “rescue” techniques for endangered ursids. The bears were euthanized, and their ovaries were transported to the laboratory within 4 h. The mean ovarian size was 2.4 × 1.8 cm (range: 2.0–3.3 × 1.5–2.2 cm). The ovaries obtained from the 2 brown bears yielded 97 oocytes (48.5/female), and 88 (90.7%) of them were morphologically classified as normal quality. Oocytes were in vitro matured at 38.5 C in 5% CO2 for 24 or 48 h in TCM-199 supplemented with 10% FBS, 1 µg/ml estradiol-17β, and 10 µg/ml FSH. In Exp. 1, morphologic evaluation of matured oocytes was conducted by measuring the diameters of oocytes with a zona pellucida (ZP) or cytoplasm without a ZP. In Exp. 2, activation was induced by applying two 20 µsec DC pulses of 2.0 kV/cm delivered by an Electro Cell Fusion Generator.
    [Show full text]
  • FSH Priming Improves Oocyte Maturation, but Priming with FSH Or Hcg Has No Effect on Subsequent Embryonic Development in an in Vitro Maturation Program Stephen M
    Theriogenology 59 (2003) 1741±1749 FSH priming improves oocyte maturation, but priming with FSH or hCG has no effect on subsequent embryonic development in an in vitro maturation program Stephen M. Junka,b,*, Arun Dharmarajanb, John L. Yovicha aPIVET Medical Center, 166±168 Cambridge Street, Leederville, Perth 6007, Australia bHuman Biology Department, School of Anatomy, University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Australia Received 15 February 2002; accepted 29 July 2002 Abstract Aim: To determine whether maturation and subsequent blastocyst development of in vitro matured oocytes can be improved by in vivo follicle stimulating hormone (FSH) or human chorionic gonadotrophin (hCG) priming, using a mouse model. Experimental design: Five groups of oocytes were used: in vivo control, in vitro matured (IVM) control, IVM after 24 h in vivo priming with FSH, IVM after 48 h in vivo priming with FSH and IVM after 16 h in vivo priming with hCG. In vitro fertilization (IVF) was performed on all groups. Oocyte maturation, fertilization, blastocyst development rates and blastocyst cell numbers were assessed for all groups. Results: Signi®cant improvement in oocyte maturation was observed in the two FSH priming groups compared with the IVM control group (P < 0:005 and P < 0:001, respectively). There were no signi®cant differences in fertilization between all ®ve groups. Blastocyst development was signi®cantly higher in the in vivo control compared to the IVM groups (P < 0:001). No signi®cant differences were observed in blastocyst cell numbers among all ®ve groups. Conclusions: While FSH priming improves the maturation rate of IVM oocytes, FSH or hCG priming does not improve development to the blastocyst stage.
    [Show full text]
  • In-Vitro Maturation of Germinal Vesicle and Metaphase I Eggs Prior to Cryopreservation Optimizes Reproductive Potential in Patients Undergoing Fertility Preservation
    CE: Namrta; GCO/26310; Total nos of Pages: 6; GCO 26310 REVIEW CURRENT OPINION In-vitro maturation of germinal vesicle and metaphase I eggs prior to cryopreservation optimizes reproductive potential in patients undergoing fertility preservation Joseph A. Leea, Lucky Sekhonb, Lawrence Grunfelda,b, and Alan B. Coppermana,b Purpose of review To evaluate current and previous findings related to a timely implementation of in-vitro maturation (IVM) of germinal vesicle, metaphase I and metaphase II oocytes with an optimal cryopreservation to determine whether IVM should be attempted prior to (fresh IVM) or IVM after cryopreservation (postthaw IVM). Mitochondrion, chromatin and spindle formation in both groups were interpreted from referenced studies to establish best management of all oocytes. Recent findings The postthaw survival of germinal vesicle, metaphase I, fresh IVM-metaphase II and control metaphase II oocytes did not differ significantly [83.3% (n ¼ 9), 86.7% (n ¼ 12), 83% (n ¼ 57) and 86% (n ¼ 68), respectively]. Overall, combined survival and maturation were significantly higher (P < 0.05) in the fresh IVM group at 63.8% (44 of 69) compared with the postthaw IVM group at 33.3% (nine of 27). Summary Conservation of retrieved immature oocytes after vaginal oocyte retrieval has become a major concern for patients, as they strive to maximize the reproductive viability of all oocytes obtained during treatment. Oocyte cryopreservation is important for patients at risk of ovarian cancer, elective fertility preservation and potentially for ovum donation. The superior maturation rate of germinal vesicle and metaphase I oocytes in the fresh IVM vs. postthaw groups provides strong impetus to mature oocytes to the metaphase II stage prior to cryopreservation.
    [Show full text]
  • In Vitro Fertilization: Four Decades of Reflections and Promises
    Biochimica et Biophysica Acta 1810 (2011) 843–852 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbagen In vitro fertilization: Four decades of reflections and promises Yulian Zhao a,⁎, Paul Brezina a, Chao-Chin Hsu b, Jairo Garcia a, Peter R. Brinsden c, Edward Wallach a a Department of Gyn/Ob, Johns Hopkins University School of Medicine, Johns Hopkins at Green Spring Station, Lutherville, MD 21093, USA b Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei 100, Taiwan c Bourn Hall Clinic, Cambridge, UK article info abstract Article history: Background: In 2010, Robert Edwards was awarded the Nobel Prize in Medicine for his pioneering work in the Received 21 March 2011 development of in vitro fertilization, a field that has touched millions of lives across the globe. Edwards Received in revised form 3 May 2011 dedicated his career to helping couples overcome infertility. He first established principles of early embryo Accepted 4 May 2011 development that served as the foundation for his later work. In the 1960s, he achieved the first human Available online 13 May 2011 fertilized oocyte in vitro while at the Johns Hopkins Hospital. He then continued his work at Cambridge University. In 1978, the world witnessed the birth of the first “test tube baby”. This achievement is a landmark Keywords: not only in the reproductive sciences but also in the history of mankind's technological evolution. Nobel Prize fi Robert Edwards Scope of review: This article outlines the development and progression of IVF from its infancy to the re ned In vitro fertilization and broadly utilized technology offered to patients today.
    [Show full text]
  • In Vitro Maturation: a Committee Opinion
    ASRM PAGES In vitro maturation: a committee opinion Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology American Society for Reproductive Medicine, Birmingham, Alabama The results of in vitro maturation (IVM) investigations suggest the potential for wider clinical application. This document discusses the efficacy of IVM as reported in the published literature to date. This document replaces the document of the same name, last published in 2013. (Fertil SterilÒ 2021;115:298-304. Ó2020 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo. Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/31765 n vitro fertilization (IVF) typically Table 1 provides some definitions of (3). Cytoplasmic maturation refers to involves ovarian stimulation with IVM currently in use. an accumulation of factors that prepare I the use of exogenous gonadotro- The human oocyte reaches its full the cytoplasm for fertilization and em- pins to induce the maturation of size (100–120 mm in diameter) at the bryonic development (17, 18). Epige- gonadotropin-sensitive follicles and small antral stage, during which time netic processes are a component of inhibit the atresia of nondominant fol- the follicular diameter is only a fraction nuclear and cytoplasmic oocyte matu- licles (1, 2). The classic use of the term of its final ovulatory diameter. ration, influencing development after in vitro maturation (IVM) refers to the The ability of an oocyte to resume and fertilization (19, 20).
    [Show full text]
  • Live Birth After in Vitro Maturation Versus Standard in Vitro
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2019-035334 on 14 April 2020. Downloaded from Live birth after in vitro maturation versus standard in vitro fertilisation for women with polycystic ovary syndrome: protocol for a non- inferiority randomised clinical trial Xiaoying Zheng,1 Wei Guo,1 Lin Zeng ,2 Danni Zheng,1 Shuo Yang,1 Lina Wang,1 Rui Wang ,3 Ben W Mol,3 Rong Li,1 Jie Qiao 1 To cite: Zheng X, Guo W, ABSTRACT Strengths and limitations of this study Zeng L, et al. Live birth after Introduction Polycystic ovary syndrome (PCOS) is the in vitro maturation versus first common cause of anovulatory infertility. Currently, in ► This is a randomised controlled trial with an ade- standard in vitro fertilisation vitro fertilisation (IVF) is recommended when conventional for women with polycystic quate sample size to evaluate in vitro maturation attempts have failed. In vitro maturation (IVM) of human ovary syndrome: protocol for (IVM) treatment in infertile women with polycystic oocytes is an emerging treatment option in infertile women a non-inferiority randomised ovary syndrome. with PCOS. It is a patient- friendly intervention, avoiding clinical trial. BMJ Open ► This study will provide evidence on whether the ex- the risk of ovarian hyperstimulation syndrome, which is 2020;10:e035334. doi:10.1136/ perimental group (IVM) is non-inferior to the stan- a serious complication of controlled ovarian stimulation bmjopen-2019-035334 dard in vitro fertilisation in terms of live birth. in the standard IVF procedure. We plan a randomised ► Prepublication history for ► The cost- effective analysis is not included in the controlled trial (RCT) to evaluate whether IVM is non- this paper is available online.
    [Show full text]
  • Age-Dependent in Vitro Maturation Efficacy of Human Oocytes
    fcell-09-667682 June 15, 2021 Time: 15:47 # 1 ORIGINAL RESEARCH published: 18 June 2021 doi: 10.3389/fcell.2021.667682 Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? Gilad Karavani1†, Peera Wasserzug-Pash2†, Talya Mordechai-Daniel1, Dvora Bauman1, Michael Klutstein2‡ and Tal Imbar1*‡ 1 Fertility Preservation Service, Department of Obstetrics and Gynecology, Hadassah Ein Kerem Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel, 2 Institute of Biomedical and Oral Research, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility Edited by: preservation technique with potential advantages over ovarian tissue cryopreservation Eleonora Napoli, University of California, Davis, (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased United States risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We Reviewed by: previously demonstrated that in vitro maturation (IVM) performed following OTC in Raquel L. Bernardino, University of Porto, Portugal fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes Volker Doetsch, available for IVM and freezing for future use. We conducted a retrospective cohort Goethe Business School, Germany study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility *Correspondence: preservation by OTC that had oocyte collected from the medium with attempted IVM. Tal Imbar [email protected] A total of 133 chemotherapy naïve patients aged 1–35 years were included in the study. †These authors share first authorship The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 ‡These authors share last authorship and ≥6 years), post-menarche (menarche-17 years), young adults (18–24 years) and adults (25–29 and 30–35 years).
    [Show full text]
  • Oocyte in Vitro Maturation: a Sytematic Review Oosit in Vitro Matürasyonu: Bir Sistematik Derleme
    Review / Derleme DOI: 10.4274/tjod.23911 Turk J Obstet Gynecol 2018;15:112-25 Oocyte in vitro maturation: A sytematic review Oosit in vitro matürasyonu: Bir sistematik derleme Şafak Hatırnaz1, Barış Ata2, Ebru Saynur Hatırnaz1, Michael Haim Dahan3, Samer Tannus3, Justin Tan3, Seang Lin Tan4 1Medicana International Hospital, In Vitro Fertilization Center, Samsun, Turkey 2Koç University Faculty of Medicine, Department of Obstetrics and Gynecology, In Vitro Fertilization Center, İstanbul, Turkey 3Mc Gill University Faculty of Medicine, Department of Obstetrics and Gynecology, Quebec, Canada 4Originelle Women and Reproductive Medicine Center, Clinic of Obstetrics and Gynecology, Montreal, Quebec, Canada Abstract In vitro maturation (IVM) is one of the most controversial aspects of assisted reproductive technology. Although it has been studied extensively, it is still not a conventional treatment option and is accepted as an alternative treatment. However, studies have shown that IVM can be used in almost all areas where in vitro fertilization (IVF) is used and it has a strong place in fertility protection and Ovarian Hyperstimulation syndrome management. The aim of this systematic review was to address all aspects of the current knowledge of IVM treatment together with the evolution of IVM and IVF. Keywords: In vitro maturation, clinical applications, laboratory procedure, pregnancy rate, fertility preservation Öz İn vitro matürasyon (IVM) yardımcı üreme teknolojilerinin en tartışmalı konularından biridir. Üzerinde çokça çalışma yapılmış olsa da halen klasik bir tedavi seçeneği değildir ve ancak alternatif tedavi olarak kabul edilmektedir. Oysa ki yapılan çalışmalarda, IVM’nin in vitro fertilizasyonun (IVF) kullanıldığı hemen tüm alanlarda kullanılabildiğini ve fertilite koruma ve Over Hiperstimülasyon sendromu yönetiminde önemli bir yer tuttuğu görülmektedir.
    [Show full text]
  • Preimplantation Genetic Testing for Aneuploidy Improves Live Birth Rates with in Vitro Produced Bovine Embryos: a Blind Retrospective Study
    cells Article Preimplantation Genetic Testing for Aneuploidy Improves Live Birth Rates with In Vitro Produced Bovine Embryos: A Blind Retrospective Study Giuseppe Silvestri 1,† , Carla Canedo-Ribeiro 1,† , María Serrano-Albal 1,†, Remi Labrecque 2, Patrick Blondin 2, Steven G. Larmer 2, Gabriele Marras 2, Desmond A.R. Tutt 3, Alan H. Handyside 1, Marta Farré 1 , Kevin D. Sinclair 3 and Darren K. Griffin 1,* 1 School of Biosciences, University of Kent, Canterbury CT2 7NH, UK; [email protected] (G.S.); [email protected] (C.C.-R.); [email protected] (M.S.-A.); [email protected] (A.H.H.); [email protected] (M.F.) 2 L’Alliance Boviteq Inc., Saint-Hyacinthe, QC J2T 5H1, Canada; [email protected] (R.L.); [email protected] (P.B.); [email protected] (S.G.L.); [email protected] (G.M.) 3 School of Biosciences, University of Nottingham, Nottingham LE12 5RD, UK; [email protected] (D.A.R.T.); [email protected] (K.D.S.) * Correspondence: d.k.griffi[email protected] † These authors contributed equally to this work. Abstract: Approximately one million in vitro produced (IVP) cattle embryos are transferred world- wide each year as a way to improve the rates of genetic gain. The most advanced programmes also Citation: Silvestri, G.; apply genomic selection at the embryonic stage by SNP genotyping and the calculation of genomic Canedo-Ribeiro, C.; Serrano-Albal, estimated breeding values (GEBVs). However, a high proportion of cattle embryos fail to establish M.; Labrecque, R.; Blondin, P.; Larmer, a pregnancy.
    [Show full text]
  • Live Birth Rate After Human Chorionic Gonadotropin Priming in Vitro Maturation in Women with Polycystic Ovary Syndrome V
    Ho et al. Journal of Ovarian Research (2018) 11:70 https://doi.org/10.1186/s13048-018-0445-5 RESEARCH Open Access Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome V. N. A. Ho1, T. D. Pham1,A.H.Le1,T.M.Ho1 and L. N. Vuong1,2* Abstract Background: In vitro maturation (IVM) has some advantages over conventional in vitro fertilization (IVF), particularly in polycystic ovary syndrome (PCOS) where the risk of ovarian hyperstimulation is high. We studied the live birth rate in a large series of PCOS women undergoing human chorionic gonadotropin (hCG)-priming IVM. Methods: This retrospective study included women with PCOS aged 18–42 years undergoing IVM with hCG priming. We reported live birth rate after the first embryo transfer and cumulative live birth rate from embryos obtained in the IVM cycle. We also performed logistic regression to assess which factors predicted number of oocytes and live birth. Results: We included 921 women (age 28.9±3.5 years, body mass index 21.8±3.1 kg/m2, infertility duration 3.7±2.6 years, 81% primary infertility, 88% first IVF attempt, 94% ovulation induction failure). Live birth rate after the first embryo transfer was 31.7%, with a cumulative live birth rate from the cycle of 33.7%. High anti-Müllerian hormone levels predicted a high number of oocytes and a high oocyte maturation rate while the opposite was the case when luteinizing hormone levels were high. Conclusions: In women with PCOS, hCG priming IVM was feasible and resulted in acceptable live birth rates.
    [Show full text]